Skip to content
← Full study record

NCT01962103 · MORE INFO

Limitations, agreements, and source contact

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors · Source last updated 2019-12-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than one year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to ninety days. Investigator must delete confidential information before submission or defer publication to permit patent applications
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialDisclosure@Celgene.com
organization
Celgene Corporation
phone
888-260-1599
title
Anne McClain, Senior Manager
Complete source fields
certain Agreement
other Details
Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than one year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to ninety days. Investigator must delete confidential information before submission or defer publication to permit patent applications
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrialDisclosure@Celgene.com
organization
Celgene Corporation
phone
888-260-1599
title
Anne McClain, Senior Manager

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice